GlaxoSmithKline

Velocity Clinical Research appoints Renata Berardocco as Executive Vice President and Managing Director for Latin America, aiming to expand its global network and leverage her experience in multisite networks and patient recruitment.

Top pharmaceutical companies like Pfizer, Roche, Johnson & Johnson, Novartis, Merck, AstraZeneca, Sanofi, GSK, AbbVie, and Bayer lead in innovation, focusing on areas such as mRNA vaccines, cancer treatments, immunology, and gene therapy, shaping the future of healthcare through R&D investments and strategic pivots.

GSK's Phase III trial GLISTEN shows positive results for linerixibat in treating cholestatic pruritus in PBC patients, meeting primary endpoint with significant itch improvement. Expected to be first global therapy for PBC itch, with 240,000 patients projected to experience cholestatic pruritus by 2030.

GSK's phase III GLISTEN study shows linerixibat significantly improves cholestatic pruritus in PBC patients, with potential to be the first global therapy for PBC-related itch. Preliminary safety data aligns with previous studies. Full data to be presented at a future medical conference.

The 2024 Access to Medicine Index reveals slow progress by major drugmakers in expanding access to essential medicines in low- and middle-income countries, with significant disparities in clinical trials and technology transfers. Despite some improvements, nearly half of essential medicines remain unregistered where disease burdens are highest, and manufacturing capacity in low-income countries remains underdeveloped. New access models show mixed results, with Novartis leading the Index, but overall progress remains slow.

Pfizer expands collaboration with Flagship Pioneering's startups, Montai Therapeutics and Ampersand Biomedicines, to discover drug candidates for lung cancer and obesity. The alliance, part of Flagship's 'Pioneering Medicines' initiative, aims to yield up to 10 new drug candidates, leveraging Flagship's startup portfolio research. Pfizer shares R&D costs and has licensing options, while Flagship startups secure funding and milestones through partnerships.

GSK's GLISTEN trial shows positive results for linerixibat, an IBAT inhibitor, in reducing itch in PBC patients, meeting primary endpoint with significant itch score reduction over 24 weeks. Linerixibat targets root cause of cholestatic pruritus, addressing a significant unmet need. Full results to be presented at a future scientific congress.

GSK’s linerixibat reduced itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage trial.